Biomarkers in mood disorders research: developing new and improved therapeutics
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Archives of Clinical Psychiatry |
Texto Completo: | https://www.revistas.usp.br/acp/article/view/96855 |
Resumo: | Background Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics. |
id |
USP-5_9d936d15e983e2666a3f70c1e9c74252 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/96855 |
network_acronym_str |
USP-5 |
network_name_str |
Archives of Clinical Psychiatry |
repository_id_str |
|
spelling |
Biomarkers in mood disorders research: developing new and improved therapeutics Background Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics. Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria2014-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/acp/article/view/9685510.1590/0101-60830000000027Archives of Clinical Psychiatry; v. 41 n. 5 (2014); 131-134Archives of Clinical Psychiatry; Vol. 41 No. 5 (2014); 131-134Revista de Psiquiatria Clínica; Vol. 41 Núm. 5 (2014); 131-1341806-938X0101-6083reponame:Archives of Clinical Psychiatryinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/acp/article/view/96855/95939Copyright (c) 2015 Archives of Clinical Psychiatryinfo:eu-repo/semantics/openAccessNICIU, MARK J. MATHEWS, DANIEL C. IONESCU, DAWN F. RICHARDS, ERICA M. FUREY, MAURA L. YUAN, PEIXIONG NUGENT, ALLISON C. HENTER, IOLINE D. MACHADO-VIEIRA, RODRIGO ZARATE JR, CARLOS A. 2015-03-27T11:30:06Zoai:revistas.usp.br:article/96855Revistahttp://www.hcnet.usp.br/ipq/revista/index.htmlPUBhttps://old.scielo.br/oai/scielo-oai.php||archives@usp.br1806-938X0101-6083opendoar:2015-03-27T11:30:06Archives of Clinical Psychiatry - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Biomarkers in mood disorders research: developing new and improved therapeutics |
title |
Biomarkers in mood disorders research: developing new and improved therapeutics |
spellingShingle |
Biomarkers in mood disorders research: developing new and improved therapeutics NICIU, MARK J. |
title_short |
Biomarkers in mood disorders research: developing new and improved therapeutics |
title_full |
Biomarkers in mood disorders research: developing new and improved therapeutics |
title_fullStr |
Biomarkers in mood disorders research: developing new and improved therapeutics |
title_full_unstemmed |
Biomarkers in mood disorders research: developing new and improved therapeutics |
title_sort |
Biomarkers in mood disorders research: developing new and improved therapeutics |
author |
NICIU, MARK J. |
author_facet |
NICIU, MARK J. MATHEWS, DANIEL C. IONESCU, DAWN F. RICHARDS, ERICA M. FUREY, MAURA L. YUAN, PEIXIONG NUGENT, ALLISON C. HENTER, IOLINE D. MACHADO-VIEIRA, RODRIGO ZARATE JR, CARLOS A. |
author_role |
author |
author2 |
MATHEWS, DANIEL C. IONESCU, DAWN F. RICHARDS, ERICA M. FUREY, MAURA L. YUAN, PEIXIONG NUGENT, ALLISON C. HENTER, IOLINE D. MACHADO-VIEIRA, RODRIGO ZARATE JR, CARLOS A. |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
NICIU, MARK J. MATHEWS, DANIEL C. IONESCU, DAWN F. RICHARDS, ERICA M. FUREY, MAURA L. YUAN, PEIXIONG NUGENT, ALLISON C. HENTER, IOLINE D. MACHADO-VIEIRA, RODRIGO ZARATE JR, CARLOS A. |
description |
Background Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/acp/article/view/96855 10.1590/0101-60830000000027 |
url |
https://www.revistas.usp.br/acp/article/view/96855 |
identifier_str_mv |
10.1590/0101-60830000000027 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/acp/article/view/96855/95939 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2015 Archives of Clinical Psychiatry info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2015 Archives of Clinical Psychiatry |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Medicina. Instituto de Psiquiatria |
dc.source.none.fl_str_mv |
Archives of Clinical Psychiatry; v. 41 n. 5 (2014); 131-134 Archives of Clinical Psychiatry; Vol. 41 No. 5 (2014); 131-134 Revista de Psiquiatria Clínica; Vol. 41 Núm. 5 (2014); 131-134 1806-938X 0101-6083 reponame:Archives of Clinical Psychiatry instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Archives of Clinical Psychiatry |
collection |
Archives of Clinical Psychiatry |
repository.name.fl_str_mv |
Archives of Clinical Psychiatry - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||archives@usp.br |
_version_ |
1800237623723163648 |